1.Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines
Ji Geun YOO ; Sung Jong LEE ; Eun Ji NAM ; Jae Hong NO ; Jeong Yeol PARK ; Jae Yun SONG ; So-Jin SHIN ; Bo Seong YUN ; Sung Taek PARK ; San-Hui LEE ; Dong Hoon SUH ; Yong Beom KIM ; Keun Ho LEE
Journal of Gynecologic Oncology 2025;36(1):e70-
		                        		
		                        			
		                        			 We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus. 
		                        		
		                        		
		                        		
		                        	
2.Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines
Ji Geun YOO ; Sung Jong LEE ; Eun Ji NAM ; Jae Hong NO ; Jeong Yeol PARK ; Jae Yun SONG ; So-Jin SHIN ; Bo Seong YUN ; Sung Taek PARK ; San-Hui LEE ; Dong Hoon SUH ; Yong Beom KIM ; Keun Ho LEE
Journal of Gynecologic Oncology 2025;36(1):e70-
		                        		
		                        			
		                        			 We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus. 
		                        		
		                        		
		                        		
		                        	
3.Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines
Ji Geun YOO ; Sung Jong LEE ; Eun Ji NAM ; Jae Hong NO ; Jeong Yeol PARK ; Jae Yun SONG ; So-Jin SHIN ; Bo Seong YUN ; Sung Taek PARK ; San-Hui LEE ; Dong Hoon SUH ; Yong Beom KIM ; Keun Ho LEE
Journal of Gynecologic Oncology 2025;36(1):e70-
		                        		
		                        			
		                        			 We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus. 
		                        		
		                        		
		                        		
		                        	
4.Human-Robot Interaction and Social Robot: The Emerging Field of Healthcare Robotics and Current and Future Perspectives for Spinal Care
In Ho HAN ; Dong Hwan KIM ; Kyoung Hyup NAM ; Jae Il LEE ; Kye-Hyung KIM ; Jong-Hwan PARK ; Ho Seok AHN
Neurospine 2024;21(3):868-877
		                        		
		                        			
		                        			 Recent advances in robotics technology and artificial intelligence (AI) have sparked increased interest in humanoid robots that resemble humans and social robots capable of interacting socially. Alongside this trend, a new field of robot research called human-robot interaction (HRI) is gaining prominence. The aim of this review paper is to introduce the fundamental concepts of HRI and social robots, examine their current applications in the medical field, and discuss the current and future prospects of HRI and social robots in spinal care. HRI is an interdisciplinary field where robotics, AI, social sciences, design, and various disciplines collaborate organically to develop robots that successfully interact with humans as the ultimate goal. While social robots are not yet widely deployed in clinical environments, ongoing HRI research encompasses various areas such as nursing and caregiving support, social and emotional assistance, rehabilitation and cognitive enhancement for the elderly, medical information provision and education, as well as patient monitoring and data collection. Although still in its early stages, research related to spinal care includes studies on robotic support for rehabilitation exercises, assistance in gait training, and questionnaire-based assessments for spinal pain. Future applications of social robots in spinal care will require diverse HRI research efforts and active involvement from spinal specialists. 
		                        		
		                        		
		                        		
		                        	
5.Human-Robot Interaction and Social Robot: The Emerging Field of Healthcare Robotics and Current and Future Perspectives for Spinal Care
In Ho HAN ; Dong Hwan KIM ; Kyoung Hyup NAM ; Jae Il LEE ; Kye-Hyung KIM ; Jong-Hwan PARK ; Ho Seok AHN
Neurospine 2024;21(3):868-877
		                        		
		                        			
		                        			 Recent advances in robotics technology and artificial intelligence (AI) have sparked increased interest in humanoid robots that resemble humans and social robots capable of interacting socially. Alongside this trend, a new field of robot research called human-robot interaction (HRI) is gaining prominence. The aim of this review paper is to introduce the fundamental concepts of HRI and social robots, examine their current applications in the medical field, and discuss the current and future prospects of HRI and social robots in spinal care. HRI is an interdisciplinary field where robotics, AI, social sciences, design, and various disciplines collaborate organically to develop robots that successfully interact with humans as the ultimate goal. While social robots are not yet widely deployed in clinical environments, ongoing HRI research encompasses various areas such as nursing and caregiving support, social and emotional assistance, rehabilitation and cognitive enhancement for the elderly, medical information provision and education, as well as patient monitoring and data collection. Although still in its early stages, research related to spinal care includes studies on robotic support for rehabilitation exercises, assistance in gait training, and questionnaire-based assessments for spinal pain. Future applications of social robots in spinal care will require diverse HRI research efforts and active involvement from spinal specialists. 
		                        		
		                        		
		                        		
		                        	
6.Large-scale salmonella outbreak associated with banh mi, Viet Nam, 2024
Tinh Huu Ho ; Phuong Hoai Hoang ; Lam Vo Thi Ngoc ; Minh Nguyen Dinh ; Dong Do Thanh ; Viet Nguyen Dinh ; O Phan Van ; Phuong Nguyen Thi Lan ; Thanh Nguyen Quoc ; Nhan Ho The ; Nhan Le Dinh Trong ; Chinh Van Dang
Western Pacific Surveillance and Response 2024;15(3):36-42
		                        		
		                        			
		                        			Objective: To investigate the cause of a foodborne outbreak that occurred in Dong Nai province, Viet Nam, in 2024, and implement control measures.
Methods: An initial investigation was conducted to confirm the outbreak, which was followed by epidemiological and environmental investigations to find the plausible causative food item. Clinical specimens and food samples were tested to identify the pathogen.
Results: A total of 547 symptomatic cases were recorded, of whom two were in severe condition requiring extracorporeal membrane oxygenation and ventilation, one of whom died. Among 99 interviewed cases, the mean incubation time was 9 hours (range 2–24 hours), with the main symptoms being fever, abdominal pain, diarrhoea and vomiting. All patients had eaten banh mi from a local bakery. Salmonella spp. were identified in food samples and clinical specimens. The bakery halted production, and the outbreak ended after 1 week.
Discussion: All the patients were exposed to only one food in common, which facilitated the investigation process. This outbreak is a reminder to small retailers and take-away shops of the importance of food safety management in preventing similar future outbreaks. All food handlers must comply with food hygiene principles, especially in hot temperatures, which boosts bacterial growth.
		                        		
		                        		
		                        		
		                        	
7.Development and Assessment of a Novel Ulcerative Colitis–Specific Quality of Life Questionnaire:A Prospective, Multi-Institutional Study
Jihye PARK ; Hyun-Soo ZHANG ; Chung Mo NAM ; Joo Sung KIM ; Young-Ho KIM ; Dong Il PARK ; Byong Duk YE ; Yoon Tae JEEN ; Sehyun KIM ; Jae Hee CHEON
Yonsei Medical Journal 2024;65(11):636-644
		                        		
		                        			 Purpose:
		                        			Interest in the quality of life (QoL) of patients with inflammatory bowel disease (IBD) has recently increased. Although measurement tools have been devised for IBD in general, there is no specific tool for measuring the QoL of patients with ulcerative colitis (UC). Therefore, we developed a QoL questionnaire specifically for patients with UC. 
		                        		
		                        			Materials and Methods:
		                        			The Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) was developed through item generation, raw-scale construction, focus group meetings, and multi-center field tests. Two hundred patients with UC were recruited for a field test of the K-UCSQ, and subsequent responses to the Inflammatory Bowel Disease Questionnaire (IBDQ) were also obtained. After performing factor analyses to ensure construct validity, the K-UCSQ was finalized as a four-domain, 28-item questionnaire. Subsequent analyses evaluated the reliability of the K-UCSQ in terms of Cronbach’s alpha, concurrent validity in comparison with the pre-established IBDQ, and predictive validity of the area under the ROC curve (AUC) for clinically relevant QoL outcomes. 
		                        		
		                        			Results:
		                        			A Cronbach’s alpha of 0.94 showed excellent reliability. Furthermore, correlation analyses demonstrated the concurrent validity of the K-UCSQ in comparison with the IBDQ. The K-UCSQ also showed high validity in predicting the perceived overall health (AUC of 0.812 vs. 0.797 using the IBDQ) and past 2-week QoL (AUC of 0.864 vs. 0.859 using the IBDQ). 
		                        		
		                        			Conclusion
		                        			The newly developed K-UCSQ is concise, bathroom problem-emphasizing, and UC-specific, suggesting that it could be a valid and reliable UC-specific instrument for QoL measurement. 
		                        		
		                        		
		                        		
		                        	
8.2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
Hyun Kuk KIM ; Seungeun RYOO ; Seung Hun LEE ; Doyeon HWANG ; Ki Hong CHOI ; Jungeun PARK ; Hyeon-Jeong LEE ; Chang-Hwan YOON ; Jang Hoon LEE ; Joo-Yong HAHN ; Young Joon HONG ; Jin Yong HWANG ; Myung Ho JEONG ; Dong Ah PARK ; Chang-Wook NAM ; Weon KIM
Korean Circulation Journal 2024;54(12):767-793
		                        		
		                        			
		                        			 Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National EvidenceBased Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy. 
		                        		
		                        		
		                        		
		                        	
9.Epidemiological and Clinical Characteristics of Women Living with HIV in Korea
Sang Min AHN ; Yong Seop LEE ; Min HAN ; Jung Ah LEE ; Jae Eun SEONG ; Yae Jee BAEK ; JongHoon HYUN ; Jung Ho KIM ; Jin Young AHN ; Dong Hyun OH ; Su Jin JEONG ; Ji Hyeon BAEK ; Nam Su KU ; Hee Kyoung CHOI ; Yoonseon PARK ; BumSik CHIN ; Young Keun KIM ; Joon Sup YEOM ; Young Hwa CHOI ; Jun Yong CHOI
Infection and Chemotherapy 2024;56(3):369-377
		                        		
		                        			 Background:
		                        			While Korea maintains a low prevalence of human immunodeficiency virus (HIV), the number of newly diagnosed cases has been steadily rising, reaching approximately 1,000 annually in recent years. The 2022 annual report from the Korea Disease Control and Prevention Agency revealed that women living with HIV (WLWH) constitute 6.4% of the total confirmed people living with the HIV population, totaling 1,219 individuals. Despite this, only a few studies have focused on WLWH in Korea. This study aims to analyze the epidemiological and clinical characteristics of WLWH in Korea. 
		                        		
		                        			Materials and Methods:
		                        			We retrospectively collected data by reviewing the medical records of all WLWH who visited 10 urban referral hospitals across Korea between January 2005 and May 2023. 
		                        		
		                        			Results:
		                        			A total of 443 WLWH were enrolled in this study. The predominant risk exposure was heterosexual contact, with 235 (53%) participants either married or cohabiting with a male partner at their initial clinic visit. Among the participants, 334 (77.7%) were Korean, 27 (6.1%) were Southeast Asian, and 19 (4.3%) were African. Antiretroviral therapy was initiated by 404 WLWH (91.2%). We observed 118 pregnancies in WLWH following their HIV diagnosis, resulting in 78 live births (66.1%), 18 induced abortions (15.2%), 10 pre-viable fetal losses (8.5%), and four stillbirths (3.4%). Over a cumulative follow-up duration of 3,202.1 years, the incidence rates of breast and cervical cancers were both 2.18 per 1,000 person-years. Additionally, the incidence rates of pelvic inflammatory disease, cervical intraepithelial neoplasm (above grade II), and osteoporosis were 4.67, 11.21, and 13.39 per 1,000 patient-years, respectively. 
		                        		
		                        			Conclusion
		                        			This is the first multicenter study to investigate the clinical and epidemiological characteristics of WLWH in Korea. The incidence and prevalence of diseases in women, including breast cancer, cervical cancer, and chronic comorbidities, are high in WLWH in Korea; therefore, further research and efforts are needed to manage these diseases. 
		                        		
		                        		
		                        		
		                        	
10.Development and Assessment of a Novel Ulcerative Colitis–Specific Quality of Life Questionnaire:A Prospective, Multi-Institutional Study
Jihye PARK ; Hyun-Soo ZHANG ; Chung Mo NAM ; Joo Sung KIM ; Young-Ho KIM ; Dong Il PARK ; Byong Duk YE ; Yoon Tae JEEN ; Sehyun KIM ; Jae Hee CHEON
Yonsei Medical Journal 2024;65(11):636-644
		                        		
		                        			 Purpose:
		                        			Interest in the quality of life (QoL) of patients with inflammatory bowel disease (IBD) has recently increased. Although measurement tools have been devised for IBD in general, there is no specific tool for measuring the QoL of patients with ulcerative colitis (UC). Therefore, we developed a QoL questionnaire specifically for patients with UC. 
		                        		
		                        			Materials and Methods:
		                        			The Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) was developed through item generation, raw-scale construction, focus group meetings, and multi-center field tests. Two hundred patients with UC were recruited for a field test of the K-UCSQ, and subsequent responses to the Inflammatory Bowel Disease Questionnaire (IBDQ) were also obtained. After performing factor analyses to ensure construct validity, the K-UCSQ was finalized as a four-domain, 28-item questionnaire. Subsequent analyses evaluated the reliability of the K-UCSQ in terms of Cronbach’s alpha, concurrent validity in comparison with the pre-established IBDQ, and predictive validity of the area under the ROC curve (AUC) for clinically relevant QoL outcomes. 
		                        		
		                        			Results:
		                        			A Cronbach’s alpha of 0.94 showed excellent reliability. Furthermore, correlation analyses demonstrated the concurrent validity of the K-UCSQ in comparison with the IBDQ. The K-UCSQ also showed high validity in predicting the perceived overall health (AUC of 0.812 vs. 0.797 using the IBDQ) and past 2-week QoL (AUC of 0.864 vs. 0.859 using the IBDQ). 
		                        		
		                        			Conclusion
		                        			The newly developed K-UCSQ is concise, bathroom problem-emphasizing, and UC-specific, suggesting that it could be a valid and reliable UC-specific instrument for QoL measurement. 
		                        		
		                        		
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail